DoxorubicinAntibiotics, AntineoplasticVincristineAntineoplastic Combined Chemotherapy ProtocolsRazoxaneCyclophosphamideAntineoplastic AgentsDrug Resistance, NeoplasmDrug CarriersLiposomesP-GlycoproteinDrug Resistance, MultiplePrednisoneBreast NeoplasmsCell Line, TumorEtoposidePolyethylene GlycolsPaclitaxelVinblastineCisplatinDaunorubicinDrug Administration ScheduleDose-Response Relationship, DrugLeukemia P388CardiotoxinsHydroxyethylrutosideDrug SynergismIfosfamideApoptosisTreatment OutcomeSarcomaTumor Cells, CulturedCombined Modality TherapyAnthracyclinesBleomycinDrug Delivery SystemsDrug ResistanceCell SurvivalDrug Screening Assays, AntitumorMitoxantroneMethotrexateDisease-Free SurvivalSurvival AnalysisInfusions, IntravenousCardiomyopathiesHeart DiseasesVerapamilHeartOsteosarcomaFluorouracilAntineoplastic Agents, PhytogenicTaxoidsDNA Topoisomerases, Type IIMice, NudeChemotherapy, AdjuvantNaphthacenesProcarbazineProdrugsNanocapsulesEpirubicinSurvival RateAclarubicinOvarian NeoplasmsXenograft Model Antitumor AssaysBone NeoplasmsSoft Tissue NeoplasmsNeoplasm TransplantationLung NeoplasmsLeukopeniaTopoisomerase II InhibitorsTime FactorsRemission InductionGenes, MDRMultidrug Resistance-Associated ProteinsNeutropeniaDacarbazineCyclosporinsLymphoma, Non-HodgkinNeoplasmsInhibitory Concentration 50MechlorethamineLymphoma, Large B-Cell, DiffuseAntibodies, Monoclonal, Murine-DerivedGranulocyte Colony-Stimulating FactorMyocardiumTissue DistributionNeoplasm StagingHodgkin DiseaseEyelidsNanoparticlesDNA DamageCarcinoma, Small Cell